全文获取类型
收费全文 | 1620499篇 |
免费 | 104545篇 |
国内免费 | 2313篇 |
专业分类
耳鼻咽喉 | 21726篇 |
儿科学 | 54297篇 |
妇产科学 | 44440篇 |
基础医学 | 228172篇 |
口腔科学 | 41362篇 |
临床医学 | 133978篇 |
内科学 | 319707篇 |
皮肤病学 | 32287篇 |
神经病学 | 130998篇 |
特种医学 | 63766篇 |
外国民族医学 | 457篇 |
外科学 | 247015篇 |
综合类 | 29482篇 |
现状与发展 | 1篇 |
一般理论 | 358篇 |
预防医学 | 126086篇 |
眼科学 | 35455篇 |
药学 | 119768篇 |
1篇 | |
中国医学 | 3646篇 |
肿瘤学 | 94355篇 |
出版年
2019年 | 11433篇 |
2018年 | 38155篇 |
2017年 | 28733篇 |
2016年 | 31893篇 |
2015年 | 17146篇 |
2014年 | 21578篇 |
2013年 | 32946篇 |
2012年 | 53776篇 |
2011年 | 68786篇 |
2010年 | 45085篇 |
2009年 | 35468篇 |
2008年 | 64400篇 |
2007年 | 70131篇 |
2006年 | 50576篇 |
2005年 | 51277篇 |
2004年 | 50182篇 |
2003年 | 49016篇 |
2002年 | 46213篇 |
2001年 | 62712篇 |
2000年 | 64320篇 |
1999年 | 54523篇 |
1998年 | 14347篇 |
1997年 | 12805篇 |
1996年 | 12874篇 |
1995年 | 12860篇 |
1994年 | 12226篇 |
1992年 | 43297篇 |
1991年 | 42524篇 |
1990年 | 42003篇 |
1989年 | 40569篇 |
1988年 | 37841篇 |
1987年 | 36909篇 |
1986年 | 35177篇 |
1985年 | 33496篇 |
1984年 | 24907篇 |
1983年 | 21653篇 |
1982年 | 12863篇 |
1981年 | 11292篇 |
1979年 | 23498篇 |
1978年 | 16452篇 |
1977年 | 14251篇 |
1976年 | 13431篇 |
1975年 | 14776篇 |
1974年 | 17405篇 |
1973年 | 16804篇 |
1972年 | 15992篇 |
1971年 | 14914篇 |
1970年 | 13879篇 |
1969年 | 13429篇 |
1968年 | 12571篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
53.
Willy Baccaglini Felipe A. Glina Cristiano Linck Pazeto Luis G. Medina Fernando Korkes Wanderley M. Bernardo Rene Sotelo Sidney Glina Giancarlo Marra Marco Moschini Xavier Cathelineau Rafael Sanchez-Salas 《Clinical genitourinary cancer》2021,19(1):3-11.e1
This meta-analysis focuses on the accuracy of upgrading to clinically significant prostate cancer (PCa) by multiparametric magnetic resonance imaging-targeted biopsy (MRI-TB) versus systematic biopsy (SB). We searched the Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Scopus, and Literatura Latino Americana em Ciências da Saúde databases through January 2020 for comparative, retrospective/prospective, paired-cohort, and randomized clinical trials with paired comparisons. The population consisted of patients with low-risk PCa in active surveillance with at least 1 index lesion on imaging. We evaluated the quality of evidence by using the Quality Assessment of Diagnostic Accuracy Studies-2 score. Group comparisons considered the differences between the area under the curve summary receiver operating characteristic curve in a 2-tailed method. We also compared the positive predictive value of the best single method (MRI-TB or SB) and the referral study test (combined biopsy, a combination of MRI-TB and SB). The meta-analysis included 6 studies enrolling 741 patients. The pooled sensitivity for the 2 groups was 0.79 (95% confidence interval, 0.74-0.83; I2 = 75%) and 0.67 (95% confidence interval, 0.63-0.74; I2 = 55.4%), respectively. The area under the curve for the MRI-TB and SB groups were 0.99 and 0.92 (P < .001), respectively. The positive predictive value for the MRI-TB and combined biopsy groups were similar. The accumulated evidence suggests better results for MRI-TB compared with SB. Therefore, use of MRI-TB alone may be preferable in patients in active surveillance harboring low-risk PCa. 相似文献
54.
55.
56.
G.R. Iball D. Tolan G.R. Avery L.H. Cope T. Hoare H. Lambie A. Lowe R.J. de Noronha C.L. Roberts M.E. Wilkinson P. Woolfall 《Clinical radiology》2021,76(8):626.e13-626.e21
57.
Mariángeles González Fernández Elena Villamañán Inmaculada Jiménez-Nácher Francisco Moreno Chamaida Plasencia Francisco Gayá Alicia Herrero Alejandro Balsa 《Reumatología clinica》2021,17(6):335-342
ObjectiveTo assess the evolution of cost per patient/year and the cost per patient/year/drug in patients with rheumatoid arthritis (RA) receiving biological treatments. To analyze and quantify the factors influencing this evolution, such as the optimization of the biological drugs, the use of biosimilars, and official discounts and discounts obtained after negotiated procedures. In addition, to assess specific clinical parameters of disease activity in these patients.MethodsRetrospective, observational study conducted in a Spanish tertiary hospital. Adult patients diagnosed with RA under treatment from 2009 to 2017 were included.Results320, 270 and 389 patients were included in 2009, 2013 and 2017, respectively. The patient/year cost decreased from 10,789€ in 2009, 7491€ in 2013 to 7116€ in 2017. In 2017, due to the established competition, discounts of 14% and 29.5% were achieved on etanercept and its biosimilar; 11.5%, 17.8%, 17.9%, 17.3% on adalimumab, certolizumab, golimumab and tocilizumab IV respectively, and 24.6% and 43.1% on infliximab and its biosimilar. The percentage of patients optimized in 2017 was 35.2%. The annual saving in 2017 was 1,288,535€ (830,000€ due to dose optimization and/or administration regimens, 249,666€ corresponding to 7.5% of the official discount and 208,868€ after negotiated procedures).ConclusionThe annual cost per patient in RA decreased considerably due to different factors, such as discounts on the purchase of drugs due to official discounts and negotiated procedures, together with the optimization of therapies, the latter being the factor that contributed most to this decrease. 相似文献
58.
There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated. 相似文献
59.
B.R. Mussmann S.D. Mørup P.M. Skov S. Foley A.S. Brenøe F. Eldahl G.M. Jørgensen H. Precht 《Radiography》2021,27(1):1-7
IntroductionOrgan-based tube current modulation (OBTCM) is designed for anterior dose reduction in Computed Tomography (CT). The purpose was to assess dose reduction capability in chest CT using three organ dose modulation systems at different kVp settings. Furthermore, noise, diagnostic image quality and tumour detection was assessed.MethodsA Lungman phantom was scanned with and without OBTCM at 80–135/140 kVp using three CT scanners; Canon Aquillion Prime, GE Revolution CT and Siemens Somatom Flash. Thermo-luminescent dosimeters were attached to the phantom surface and all scans were repeated five times. Image noise was measured in three ROIs at the level of the carina. Three observers visually scored the images using a fivestep scale. A Wilcoxon Signed-Rank test was used for statistical analysis of differences.ResultsUsing the GE revolution CT scanner, dose reductions between 1.10 mSv (12%) and 1.56 mSv (24%) (p < 0.01) were found in the anterior segment and no differences posteriorly and laterally. Total dose reductions between 0.64 (8%) and 0.91 mSv (13%) were found across kVp levels (p < 0.00001). Maximum noise increase with OBTCM was 0.8 HU. With the Canon system, anterior dose reductions of 6–10% and total dose reduction of 0.74–0.76 mSv across kVp levels (p < 0.001) were found with a maximum noise increase of 1.1 HU. For the Siemens system, dose increased by 22–51% anteriorly; except at 100 kVp where no dose difference was found. Noise decreased by 1 to 1.5 HU.ConclusionOrgan based tube current modulation is capable of anterior and total dose reduction with minimal loss of image quality in vendors that do not increase posterior dose.Implications for practiceThis research highlights the importance of being familiar with dose reduction technologies. 相似文献
60.